Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of December 2013 for Redhill Biopharma Ltd., a foreign private issuer based in Tel Aviv, Israel. The filing incorporates by reference a press release dated December 31, 2013, announcing a definitive agreement for a private placement.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the period. The primary financial event disclosed is a capital raise agreement.
- Private Placement Amount: $2.5 million
- Investor: Broadfin Capital LLC
Material Changes
The material change reported is the execution of a definitive agreement to raise $2.5 million through a private placement from Broadfin Capital LLC. No comparative financial data or changes in operating metrics versus prior periods are provided in this specific filing.
Guidance, Outlook, and Risks
The filing text does not contain management commentary on future guidance, outlook, specific risks, contingencies, or unusual items beyond the announcement of the financing agreement.
Investor Verification Checklist
- Verify the closing date and final terms of the $2.5 million private placement with Broadfin Capital LLC.
- Confirm the number of shares issued and the price per share in the private placement.
- Review the company's most recent Form 20-F for comprehensive financial statements, as this 6-K does not contain audited financial data.
- Assess the impact of this capital raise on the company's cash runway and dilution to existing shareholders.